Oblique Therapeutics identifies epitope for SARS-CoV-2 antibodies

By The Science Advisory Board staff writers

June 11, 2020 -- Oblique Therapeutics has used its Abiprot antibody discovery platform to identify an epitope in SARS-CoV-2 that may facilitate the generation of new neutralizing antibodies to treat COVID-19.

Abiprot is based on a tailored molecular reporter system and proteomics. The system can identify high-affinity antibody binding sites in any given protein with single-amino acid resolution.

By working to map additional epitopes on the SARS-CoV-2 surface isolated from the nasal swab of a COVID-19 patient, the company identified the new epitope in a pilot study. The company will make all of the results freely available for vaccine and antibody-developing pharmaceutical and biotechnology companies.

The research to discover the epitope was conducted in collaboration with scientists from institutions in Sweden including Sahlgrenska University Hospital, Sahlgrenska Academy, University of Gothenburg, and Karolinska Institute with support from Nanoxis Consulting.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here